Switzerland-based clinical-stage biopharmaceutical company Urovant Sciences announced the pricing of its initial public offering of 10 million common shares at a price to the public of $14.00 per share, for total gross proceeds of $140 million, before deducting underwriting discounts and commissions and other offering expenses payable by Urovant.

In addition, Urovant has granted the underwriters a 30-day option to purchase up to 1.5 million additional common shares at the initial public offering price less the underwriting discounts and commissions.

All of the common shares are being offered by Urovant.

The offering is expected to close on October 1, 2018, subject to customary closing conditions.